All articles
Evidence-led research on repurposed compounds and the protocols people actually ask about — cited to primary literature and reviewed for accuracy.
Curcumin-Selenium Macromolecule Destroys A549 Lung Cancer Cells
A novel bifunctional macromolecular system combining curcumin with selenium-loaded bovine serum albumin triggers programmed cell death (apoptosis) in lung adenocarcinoma cells in vitro.
Artemisinin Silk-Fibroin Nanoparticles Show Strong Preclinical Activity Against Melanoma
An August 2026 study in RSC Advances reports silk-fibroin artemisinin nanoparticles reduced melanoma cell viability to approximately 23% in preclinical testing. This is early in vitro evidence only.
Curcumin Improves Mitotane Efficacy in Adrenocortical Carcinoma: New 2026 Study
A 2026 preclinical study in Cells demonstrates that curcumin enhances mitotane's anti-tumor effects in adrenocortical carcinoma through metabolic rewiring and liver protection.
Curcumin Exerts Distinct Anti-Tumor Effects in Liver Cancer via NRF1α/NRF2 Metabolic Reprogramming (2026)
A 2026 study in Bioorganic Chemistry demonstrates curcumin's distinct anti-tumor effects in liver cancer through NRF1α/NRF2 metabolic reprogramming.
Curcumin + 5-FU Microneedles for Skin Cancer: A 3D-Printed Delivery Platform (2026)
A 2026 study from Queen's University Belfast reports a 3D-printed microneedle system that co-delivers curcumin and 5-FU for localized skin cancer therapy. The platform achieves >95% insertion efficiency and controlled biphasic release in preclinical characterization.
Curcumin Targets NRF1α in Hepatocellular Carcinoma: 2026 Preclinical Study
A 2026 study in Bioorganic Chemistry reveals that curcumin suppresses liver cancer primarily through NRF1α stabilization, with synthetic lethality in NRF1α-deficient tumors.
Curcumin Blocks Fusobacterium-Driven Esophageal Cancer via TLR4/MYD88/TRIF/STAT3 Axis, Restoring Chemosensitivity in Preclinical Models (2026)
A 2026 study in Journal of Gastroenterology demonstrates curcumin blocks Fusobacterium nucleatum-driven esophageal squamous cell carcinoma by inhibiting the TLR4/MYD88/TRIF/STAT3 axis, suppressing tumor growth and restoring chemotherapy sensitivity in cell and animal models.
Ivermectin Identified as Liver Cancer Candidate in 2026 Study
Researchers used multi-omics profiling and computational drug screening to identify ivermectin as a potential candidate for hepatocellular carcinoma. The study is in silico and requires experimental validation.
Fenbendazole Encapsulated by Cucurbiturils: New Nanocarrier Design for Cancer Drug Delivery (2026)
A 2026 computational study investigates encapsulating fenbendazole within cucurbituril nanocarriers to improve aqueous solubility and stability for potential cancer therapy applications.
Mebendazole Shows Anticancer Activity in Ovarian Cancer Spheroids (2026 Study)
A 2026 preclinical study uses optical coherence tomography to evaluate mebendazole's anticancer activity in ovarian cancer spheroids, including cisplatin-resistant models.
Ivermectin Neurotoxicity in Breast Cancer: Life-Threatening Case Report
A 73-year-old breast cancer patient developed life-threatening neurotoxicity after self-administering high-dose ivermectin. She recovered fully after 48 hours of intensive care. The case highlights the dangers of unsupervised off-label use.
Sugar-Linked Curcumin Complex Kills Breast Tumor Cells via GLUT Transporters (2026)
A 2026 in-vitro study in Scientific Reports describes a sugar-linked curcumin complex that selectively targets glucose transporters overexpressed in breast cancer cells, achieving cytotoxicity with an IC50 of 7.51 μg/mL.
Nothing here yet.